- Home
- REPL
REPL
Replimune Group Inc.
as of 12-12-2025 3:58pm EST
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | WOBURN |
| Market Cap: | 721.7M | IPO Year: | 2018 |
| Target Price: | $12.00 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.68 - $14.79 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered REPL Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Replimune Group Inc. (REPL)
Director
Avg Cost/Share
$10.40
Shares
3,169
Total Value
$32,957.60
Owned After
0
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$11.13
Shares
10,000
Total Value
$111,300.00
Owned After
333,576
SEC Form 4
Chief Commercial Officer
Avg Cost/Share
$9.10
Shares
5,208
Total Value
$47,392.80
Owned After
123,088
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$9.10
Shares
7,248
Total Value
$65,956.80
Owned After
139,685
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Dhingra Kapil | REPL | Director | Dec 9, 2025 | Sell | $10.40 | 3,169 | $32,957.60 | 0 | |
| Patel Sushil | REPL | Chief Executive Officer | Dec 2, 2025 | Sell | $11.13 | 10,000 | $111,300.00 | 333,576 | |
| Sarchi Christopher | REPL | Chief Commercial Officer | Nov 17, 2025 | Sell | $9.10 | 5,208 | $47,392.80 | 123,088 | |
| Xynos Konstantinos | REPL | Chief Medical Officer | Nov 17, 2025 | Sell | $9.10 | 7,248 | $65,956.80 | 139,685 |
Compare REPL vs Leading Stocks
See how REPL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "REPL Replimune Group Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.